Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $5.4 million.

  • Evoke Pharma's Operating Expenses rose 3761.12% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 3514.37%. This contributed to the annual value of $15.5 million for FY2024, which is 2253.52% up from last year.
  • Per Evoke Pharma's latest filing, its Operating Expenses stood at $5.4 million for Q3 2025, which was up 3761.12% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Evoke Pharma's Operating Expenses peaked at $5.4 million during Q3 2025, and registered a low of $1.9 million during Q4 2021.
  • Its 5-year average for Operating Expenses is $3.3 million, with a median of $3.0 million in 2023.
  • In the last 5 years, Evoke Pharma's Operating Expenses plummeted by 6546.1% in 2021 and then skyrocketed by 4220.65% in 2023.
  • Quarter analysis of 5 years shows Evoke Pharma's Operating Expenses stood at $1.9 million in 2021, then soared by 31.35% to $2.5 million in 2022, then soared by 42.21% to $3.6 million in 2023, then increased by 26.32% to $4.5 million in 2024, then increased by 20.43% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $5.3 million for Q2 2025, and $4.4 million during Q1 2025.